Patient- and disease-related characteristics of nonmanipulated unrelated bone marrow (UBMT), T-cell–depleted unrelated bone marrow donor (T-UBMT), and umbilical unrelated cord blood transplants (UCBT)
| Characteristics . | UBMT (n = 262) . | T-UBMT (n = 180) . | UCBT (n = 99) . | P value* . |
|---|---|---|---|---|
| Patient-related | ||||
| Age, years | 8 (5-12) | 8 (6-12) | 6 (2.5-10) | .0004 |
| Missing data | 0 | 0 | 0 | |
| < 2 yr | 20 (8%) | 5 (3%) | 21 (21%) | .0001 |
| < 6 yr | 79 (30%) | 58 (32%) | 54 (55%) | .0001 |
| Gender | ||||
| Male | 159 (61%) | 118 (66%) | 58 (59%) | .44 |
| Female | 103 (39%) | 62 (34%) | 41 (41%) | |
| Weight, kg | 28 (20-42) | 28 (20-41) | 21 (13-34) | .0001 |
| Missing data | 3 (1%) | 11 (6%) | 0 | |
| Positive recipient CMV serology prior to transplant | 119 (46%) | 48 (27%) | 47 (48%) | .0001 |
| Missing data | 1 (0.4%) | 0 | 1 (1%) | |
| Disease-related | ||||
| Diagnosis | ||||
| ALL | 195 (74%) | 145 (81%) | 65 (66%) | .014 |
| AML | 49 (19%) | 24 (13%) | 30 (30%) | |
| Secondary leukemia | 18 (7%) | 11 (6%) | 4 (4%) | |
| Previous transplant for relapse† | 10 (4%) | 3 (2%) | 14 (14%) | .0001 |
| Missing data | 9 (3%) | 2 (1%) | 0 | |
| Immunophenotype (only for ALL) B (B + preB + null)/T/Hybrid (biphenotypic or others) | 153/23/8 | 110/27/6 | 46/10/7 | .11 |
| Missing data | 11 (4%) | 2 (1%) | 2 (2%) | |
| FAB (only for AML) M0 + M1 + M5 + M6 + M7 vs M3 + M4 | 39/7 | 15/7 | 20/9 | .17 |
| Missing data | 3 (1%) | 2 (1%) | 1 (1%) | |
| Karyotype | ||||
| Unfavorable t(9;22), 11q23, t(4;11), monosomy 7, 5q- | 48 (18%) | 31 (17%) | 19 (19%) | .93 |
| Intermediate (Others or normal) | 135 (52%) | 102 (57%) | 58 (59%) | |
| Favorable (hyperploidy + inv16 + t(8;21) + t(15,17) | 22 (8%) | 13 (7%) | 8 (8%) | |
| Missing data | 57 (22%) | 34 (19%) | 14 (14%) | |
| Time interval from diagnosis to transplantation, months | 20 (8-42) | 24 (8-41) | 15 (8-31) | .10 |
| Missing data | 0 | 0 | 0 | |
| Median days from last CR to transplantation (only for patients in CR at time of transplantation) | 113 (70-190) | 109 (76-156) | 84 (52-139) | .001 |
| (n = 210) | (n = 163) | (n = 81) | ||
| First relapse on therapy | 85 (45%) | 55 (42%) | 44 (58%) | .08 |
| First relapse off therapy | 105 (55%) | 75 (58%) | 32 (42%) | |
| Missing data | 1 (0.4%) | 2 (1%) | 0 | |
| Median days from first CR to first relapse | 650 (296-939) | 744 (388-1019) | 400 (184-814) | .001 |
| (n = 187) | (n = 131) | (n = 76) | ||
| Status at time of transplantation | ||||
| First CR | 59 (23%) | 43 (24%) | 18 (18%) | .04 |
| Second CR | 102 (39%) | 90 (50%) | 49 (49%) | |
| ≥ Third CR | 49 (19%) | 30 (17%) | 14 (14%) | |
| Advanced (refractory/partial response/relapse/first acute phase) | 52 (20%) | 17 (9%) | 18 (18%) | |
| Poor Risk (≥ 3CR + advanced) | 101 (39%) | 47 (26%) | 32 (32%) | .02 |
| Good risk (1CR + 2CR) | 161 (61%) | 133 (74%) | 67 (68%) |
| Characteristics . | UBMT (n = 262) . | T-UBMT (n = 180) . | UCBT (n = 99) . | P value* . |
|---|---|---|---|---|
| Patient-related | ||||
| Age, years | 8 (5-12) | 8 (6-12) | 6 (2.5-10) | .0004 |
| Missing data | 0 | 0 | 0 | |
| < 2 yr | 20 (8%) | 5 (3%) | 21 (21%) | .0001 |
| < 6 yr | 79 (30%) | 58 (32%) | 54 (55%) | .0001 |
| Gender | ||||
| Male | 159 (61%) | 118 (66%) | 58 (59%) | .44 |
| Female | 103 (39%) | 62 (34%) | 41 (41%) | |
| Weight, kg | 28 (20-42) | 28 (20-41) | 21 (13-34) | .0001 |
| Missing data | 3 (1%) | 11 (6%) | 0 | |
| Positive recipient CMV serology prior to transplant | 119 (46%) | 48 (27%) | 47 (48%) | .0001 |
| Missing data | 1 (0.4%) | 0 | 1 (1%) | |
| Disease-related | ||||
| Diagnosis | ||||
| ALL | 195 (74%) | 145 (81%) | 65 (66%) | .014 |
| AML | 49 (19%) | 24 (13%) | 30 (30%) | |
| Secondary leukemia | 18 (7%) | 11 (6%) | 4 (4%) | |
| Previous transplant for relapse† | 10 (4%) | 3 (2%) | 14 (14%) | .0001 |
| Missing data | 9 (3%) | 2 (1%) | 0 | |
| Immunophenotype (only for ALL) B (B + preB + null)/T/Hybrid (biphenotypic or others) | 153/23/8 | 110/27/6 | 46/10/7 | .11 |
| Missing data | 11 (4%) | 2 (1%) | 2 (2%) | |
| FAB (only for AML) M0 + M1 + M5 + M6 + M7 vs M3 + M4 | 39/7 | 15/7 | 20/9 | .17 |
| Missing data | 3 (1%) | 2 (1%) | 1 (1%) | |
| Karyotype | ||||
| Unfavorable t(9;22), 11q23, t(4;11), monosomy 7, 5q- | 48 (18%) | 31 (17%) | 19 (19%) | .93 |
| Intermediate (Others or normal) | 135 (52%) | 102 (57%) | 58 (59%) | |
| Favorable (hyperploidy + inv16 + t(8;21) + t(15,17) | 22 (8%) | 13 (7%) | 8 (8%) | |
| Missing data | 57 (22%) | 34 (19%) | 14 (14%) | |
| Time interval from diagnosis to transplantation, months | 20 (8-42) | 24 (8-41) | 15 (8-31) | .10 |
| Missing data | 0 | 0 | 0 | |
| Median days from last CR to transplantation (only for patients in CR at time of transplantation) | 113 (70-190) | 109 (76-156) | 84 (52-139) | .001 |
| (n = 210) | (n = 163) | (n = 81) | ||
| First relapse on therapy | 85 (45%) | 55 (42%) | 44 (58%) | .08 |
| First relapse off therapy | 105 (55%) | 75 (58%) | 32 (42%) | |
| Missing data | 1 (0.4%) | 2 (1%) | 0 | |
| Median days from first CR to first relapse | 650 (296-939) | 744 (388-1019) | 400 (184-814) | .001 |
| (n = 187) | (n = 131) | (n = 76) | ||
| Status at time of transplantation | ||||
| First CR | 59 (23%) | 43 (24%) | 18 (18%) | .04 |
| Second CR | 102 (39%) | 90 (50%) | 49 (49%) | |
| ≥ Third CR | 49 (19%) | 30 (17%) | 14 (14%) | |
| Advanced (refractory/partial response/relapse/first acute phase) | 52 (20%) | 17 (9%) | 18 (18%) | |
| Poor Risk (≥ 3CR + advanced) | 101 (39%) | 47 (26%) | 32 (32%) | .02 |
| Good risk (1CR + 2CR) | 161 (61%) | 133 (74%) | 67 (68%) |
P value: Fisher test for categoric variables and Kruskal-Wallis for continuous variables. For continuous variables, median (25th-75th percentiles) are given; for qualitative variables, sample size (percentages) are given within each strata.
Autologous or allogeneic transplant for relapse.
ALL indicates acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; FAB, French-American-British classification; and CR, complete remission.